Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(2.19)
# 1,444
Out of 4,667 analysts
468
Total ratings
38.62%
Success rate
-4.06%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterates: Buy | $617 | $591.82 | +4.25% | 32 | Nov 20, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $14 | $4.91 | +185.13% | 21 | Nov 20, 2024 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $50 | $40.65 | +23.00% | 23 | Nov 19, 2024 | |
| CABA Cabaletta Bio | Reiterates: Buy | $25 | $2.26 | +1,006.19% | 22 | Nov 18, 2024 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $3.18 | +277.36% | 15 | Nov 15, 2024 | |
| SCPH scPharmaceuticals | Reiterates: Buy | $18 | $3.36 | +435.71% | 11 | Nov 14, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Neutral | $2 | $0.31 | +547.25% | 19 | Nov 14, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $34 | $19.79 | +71.80% | 13 | Nov 14, 2024 | |
| BHVN Biohaven | Reiterates: Buy | $59 | $46.83 | +25.99% | 11 | Nov 14, 2024 | |
| ROIV Roivant Sciences | Reiterates: Buy | $18 | $11.49 | +56.66% | 16 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $118 | $62.55 | +88.65% | 12 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $81 | $56.07 | +44.46% | 22 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $9.79 | +206.44% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $39.34 | +34.72% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.6 | $3.80 | +73.68% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.01 | +179.44% | 14 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $26.17 | +94.88% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $120 | $73.68 | +62.87% | 20 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $12.63 | +113.78% | 23 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.10 | +990.91% | 21 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.30 | +50.94% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $57 | $27.49 | +107.35% | 23 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.12 | +135.85% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $37 | $27.91 | +32.57% | 22 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.56 | +787.15% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $9.97 | +50.45% | 13 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.28 | +468.18% | 13 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.34 | +646.27% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $18.46 | -45.83% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $203.67 | -10.64% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $5.23 | +258.51% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $23.39 | -23.04% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $17.03 | -53.02% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $17.03 | +205.34% | 2 | Jun 11, 2019 |
argenx SE
Nov 20, 2024
Reiterates: Buy
Price Target: $617
Current: $591.82
Upside: +4.25%
Sage Therapeutics
Nov 20, 2024
Reiterates: Neutral
Price Target: $14
Current: $4.91
Upside: +185.13%
Protagonist Therapeutics
Nov 19, 2024
Reiterates: Buy
Price Target: $50
Current: $40.65
Upside: +23.00%
Cabaletta Bio
Nov 18, 2024
Reiterates: Buy
Price Target: $25
Current: $2.26
Upside: +1,006.19%
Daré Bioscience
Nov 15, 2024
Reiterates: Buy
Price Target: $12
Current: $3.18
Upside: +277.36%
scPharmaceuticals
Nov 14, 2024
Reiterates: Buy
Price Target: $18
Current: $3.36
Upside: +435.71%
Marinus Pharmaceuticals
Nov 14, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.31
Upside: +547.25%
Viridian Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $19.79
Upside: +71.80%
Biohaven
Nov 14, 2024
Reiterates: Buy
Price Target: $59
Current: $46.83
Upside: +25.99%
Roivant Sciences
Nov 13, 2024
Reiterates: Buy
Price Target: $18
Current: $11.49
Upside: +56.66%
Nov 13, 2024
Maintains: Buy
Price Target: $70 → $118
Current: $62.55
Upside: +88.65%
Nov 13, 2024
Maintains: Buy
Price Target: $69 → $81
Current: $56.07
Upside: +44.46%
Nov 13, 2024
Reiterates: Buy
Price Target: $30
Current: $9.79
Upside: +206.44%
Nov 13, 2024
Reiterates: Buy
Price Target: $53
Current: $39.34
Upside: +34.72%
Nov 8, 2024
Reiterates: Neutral
Price Target: $6.6
Current: $3.80
Upside: +73.68%
Nov 8, 2024
Reiterates: Buy
Price Target: $14
Current: $5.01
Upside: +179.44%
Nov 8, 2024
Reiterates: Buy
Price Target: $51
Current: $26.17
Upside: +94.88%
Nov 7, 2024
Reiterates: Buy
Price Target: $120
Current: $73.68
Upside: +62.87%
Nov 7, 2024
Reiterates: Buy
Price Target: $27
Current: $12.63
Upside: +113.78%
Nov 7, 2024
Reiterates: Buy
Price Target: $12
Current: $1.10
Upside: +990.91%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $5.30
Upside: +50.94%
Nov 6, 2024
Maintains: Buy
Price Target: $83 → $57
Current: $27.49
Upside: +107.35%
Nov 6, 2024
Reiterates: Neutral
Price Target: $5
Current: $2.12
Upside: +135.85%
Oct 25, 2024
Reiterates: Neutral
Price Target: $37
Current: $27.91
Upside: +32.57%
Oct 1, 2024
Reiterates: Buy
Price Target: $5
Current: $0.56
Upside: +787.15%
Sep 16, 2024
Reiterates: Buy
Price Target: $15
Current: $9.97
Upside: +50.45%
Aug 15, 2024
Reiterates: Buy
Price Target: $30
Current: $5.28
Upside: +468.18%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.34
Upside: +646.27%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $18.46
Upside: -45.83%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $203.67
Upside: -10.64%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $5.23
Upside: +258.51%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $23.39
Upside: -23.04%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $17.03
Upside: -53.02%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $17.03
Upside: +205.34%